12:00 AM
May 23, 2005
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MG98: Phase II data

Data from the Phase II Step 1 trial of MG98 in combination with interferon alpha to treat renal cell cancer showed that 1 patient on the continuous infusion schedule experienced a confirmed partial response...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD